XinThera, Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Pharmaceuticals
See more in Biomedtracker
Latest on XinThera, Inc.
Scrip
• By Andrew McConaghie
AstraZeneca may just have found a worthy successor to its blockbuster PARP inhibitor drug Lynparza. New Phase I/II results from the next generation therapy saruparib just unveiled suggest that it cou
Scrip
• By Mandy Jackson
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical